TY - JOUR
T1 - Early outcome after paclitaxel-eluting stents in patients with acute and subacute myocardial infarction. A clinical study
AU - Margheri, Massimo
AU - Giglioli, Cristina
AU - Comeglio, Marco
AU - Valente, Serafina
AU - Chechi, Tania
AU - Falai, Massimiliano
AU - Becherini, Roberto
AU - Vittori, Guido
AU - Parigi, Elena
AU - Lazzeri, Chiara
AU - Gensini, Gian Franco
PY - 2004/7
Y1 - 2004/7
N2 - Background. Paclitaxel-eluting stents (PES) have been proven to prevent in-stent restenosis in patients submitted to elective percutaneous coronary intervention. No data are so far available about the safety and efficacy of PES in acute and subacute myocardial infarction. The aim of the present investigation was to evaluate the occurrence of in-hospital adverse events in patients with acute and subacute myocardial infarction submitted to PES implantation. Methods. From June 1 to July 31, 2003, we implanted 53 PES in 43 consecutive patients with acute (34 patients) and subacute (9 patients) myocardial infarction. Results. In 65.1% of the patients the culprit lesion was located in the left anterior descending artery. Direct stenting was performed in 27.9% and glycoprotein IIb/IIIa inhibitors were used in 74.4%. Before the procedure a TIMI flow 0-1 was present in 46.5% while post-procedural TIMI flow 3 was achieved in all patients. A pre-procedural TIMI thrombus grade 2 to 5 was present in 67.8%. No death, reinfarction, early post-infarction angina or any other episode referable to in-stent thrombosis were observed during hospitalization. No patient was submitted to target lesion revascularization. At short-term follow-up with a mean duration of 118 ± 75 days from discharge no cardiac or noncardiac death, reinfarction or any other major adverse coronary events were reported in the study population and no target lesion revascularization was performed. Conclusions. In this study, PES implant in patients with acute and subacute myocardial infarction was safe, with an early outcome comparable to conventional standard stents and no adverse events related to acute or subacute thrombosis.
AB - Background. Paclitaxel-eluting stents (PES) have been proven to prevent in-stent restenosis in patients submitted to elective percutaneous coronary intervention. No data are so far available about the safety and efficacy of PES in acute and subacute myocardial infarction. The aim of the present investigation was to evaluate the occurrence of in-hospital adverse events in patients with acute and subacute myocardial infarction submitted to PES implantation. Methods. From June 1 to July 31, 2003, we implanted 53 PES in 43 consecutive patients with acute (34 patients) and subacute (9 patients) myocardial infarction. Results. In 65.1% of the patients the culprit lesion was located in the left anterior descending artery. Direct stenting was performed in 27.9% and glycoprotein IIb/IIIa inhibitors were used in 74.4%. Before the procedure a TIMI flow 0-1 was present in 46.5% while post-procedural TIMI flow 3 was achieved in all patients. A pre-procedural TIMI thrombus grade 2 to 5 was present in 67.8%. No death, reinfarction, early post-infarction angina or any other episode referable to in-stent thrombosis were observed during hospitalization. No patient was submitted to target lesion revascularization. At short-term follow-up with a mean duration of 118 ± 75 days from discharge no cardiac or noncardiac death, reinfarction or any other major adverse coronary events were reported in the study population and no target lesion revascularization was performed. Conclusions. In this study, PES implant in patients with acute and subacute myocardial infarction was safe, with an early outcome comparable to conventional standard stents and no adverse events related to acute or subacute thrombosis.
KW - Drugs
KW - Myocardial infarction
KW - Stents
UR - http://www.scopus.com/inward/record.url?scp=16544365959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16544365959&partnerID=8YFLogxK
M3 - Article
C2 - 15487272
AN - SCOPUS:16544365959
VL - 5
SP - 536
EP - 540
JO - Italian Heart Journal
JF - Italian Heart Journal
SN - 1129-471X
IS - 7
ER -